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Local Immune Responsiveness in Skin Tumors
R Dummer and M Urosevic
Department of Dermatology, University Hospital of Zurich, Switzerland
Cutaneous neoplasias include malignancies derived from resident and non resident
cutaneous cell populations. Melanomas and epithelial cutaneous tumors present all
the preconditions for a successful rejection by the immune system involving cell
mediated mechanisms and humoral immune reactions mediated by antibodies. For
the local immune responsiveness, cell mediated immune mechanisms are most
relevant. They have to be distinguished into innate and adaptive immune
responses. Many local immune interventions primarily induce innate immune
responses. Imiquimod, a toll-like receptor 7 agonist, used topically for the treatment
of genital warts and epithelial skin cancers induces the local recruitment of
plasmacytoid dendritic cells into the tumoral microenvironment. This results in
high levels of interferon alpha production. In another system of local immunother-
apy using adenoviruses innate immune responses including neutrophils and
eosinophils are observed in the first phase. In later stages, adaptive immune
responses mediated by cytotoxic T-lymphocytes are observed. Our own investiga-
tions in epithelial skin cancers and cutaneous T-cell lymphomas treated by local
application of Imiquimod suggest, that the local recruitment of interferon producing
plasmacytoid dendritic cells is crucial for the antitumor effect and is closely linked
to the clinical science of inflammation.
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Efficacy of Immune Response Modifiers in the Treatment of Actinic
Keratoses
A Hauschild
Department of Dermatology, University of Kiel, Germany
Actinic keratoses (Aks) are epidermal lesions that generally occur in fair-skinned
individuals with long-term UV exposure. Among the new treatment modalities for
actinic keratoses are immune response modifiers (IRMs) that interfere with toll-like
receptor 7 leading to a stimulation of monocytes/macrophages and dendritic cells
to produce Interferon and other pro-inflammatory cytokines leading to a cell-
mediated immunity. Imiquimod 5% cream has shown reasonable therapeutic
efficacy in the management of various dermatoses such as genital warts and BCCs
recently. Several trials suggest a rate of complete responses between 50 and 80% in
actinic keratoses. Studies from the US, Europe and Australia have evaluated the
efficacy and safety mostly in patients with actinic keratoses confined to the face and
scalp. Vehicle-controlled, double-blinded studies demonstrated consistently a
statistical significant superiority compared to placebo alone. The imiquimod cream
was applied 3-5 times a week for periods of 6-16 weeks or until the lesions have
cleared completely. All trials consisted of a biopsy control after treatment
discontinuation. Of interest, it turned out that patients with moderate to severe
local inflammatory reactions have a higher likelihood for a complete clearance of
Aks. This needs to be stressed to maintain the compliance of patients during the
administration of imiquimod. In conclusion, all clinical trials suggest that
Imiquimod 5% cream is a useful therapeutic option in the management of Aks.
However, longer follow-up studies are required to assess if the immune reaction
stimulated by imiquimod results in a reduced recurrence rate within the treatment
areas even after many years.
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Perspectives Applications of Imiquimod Treatment in Squamous Cell
Carcinoma
K Peris
Department of Dermatology, University of L’Aquila, L’Aquila, Italy
Imiquimod has been successfully used for treatment of various epithelial cutaneous
neoplasms. The objective of our study was to evaluate the efficacy and tolerability
of imiquimod 5% cream for treatment of Bowen’s disease and invasive squamous
cell carcinoma (SCC) in patients who were unsuitable candidates for surgery. Five
Bowen’s disease and 7 invasive SCC lesions on 10 patients were treated with
imiquimod once-daily five times a week for a maximum of 16 weeks. Individual
lesions ranged in size from 1.5 to 6 cm (mean: 3.17 cm). Bowen’s disease lesions
were located on the right (3) and left leg (1) and on the wrist (1), and invasive SCC
lesions were located on the face (5), ear (1) and right leg (1). All patients enrolled in
the study completed the treatment. After 8-12 weeks of treatment, 4 of 5 (80%)
Bowen’s disease lesions in 4 patients and 5 of 7 (71.4%) invasive SCCs in 4 patients
showed complete clinicopathologic regression. The remaining 3 lesions showed
partial regression after 16 weeks of treatment. Local adverse effects consisted of
erythema and pruritus, erosion, ulceration, burning and vescicle formation. No
recurrence has been detected after a follow-up period of 24-38 months (mean: 31
months). In conclusion, topical application of imiquimod 5% cream might
represent an adjunctive topical treatment in selected cases of Bowen’s disease
and invasive SCC.
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